|
Jubilant Pharmova Limited (jublpharma.ns) valoración de DCF
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Jubilant Pharmova Limited (JUBLPHARMA.NS) Bundle
¡Explore el potencial financiero de Jubilant Pharmova Limited (Juvpharmans) con nuestra calculadora DCF fácil de usar! Ingrese sus proyecciones para el crecimiento, los márgenes de beneficio y los gastos para calcular el valor intrínseco de Jubilant Pharmova Limited (Juvpharmans) y mejorar su toma de decisiones de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 89,765.4 | 59,638.8 | 60,591.7 | 62,193.0 | 66,448.0 | 62,713.7 | 59,189.3 | 55,863.0 | 52,723.6 | 49,760.6 |
| Revenue Growth, % | 0 | -33.56 | 1.6 | 2.64 | 6.84 | -5.62 | -5.62 | -5.62 | -5.62 | -5.62 |
| EBITDA | 15,524.3 | 13,928.7 | 11,676.2 | 7,577.5 | 8,088.0 | 10,570.5 | 9,976.4 | 9,415.8 | 8,886.6 | 8,387.2 |
| EBITDA, % | 17.29 | 23.36 | 19.27 | 12.18 | 12.17 | 16.86 | 16.86 | 16.86 | 16.86 | 16.86 |
| Depreciation | 3,398.4 | 3,489.5 | 3,817.0 | 5,540.3 | 3,819.0 | 3,837.1 | 3,621.4 | 3,417.9 | 3,225.8 | 3,044.6 |
| Depreciation, % | 3.79 | 5.85 | 6.3 | 8.91 | 5.75 | 6.12 | 6.12 | 6.12 | 6.12 | 6.12 |
| EBIT | 12,125.9 | 10,439.2 | 7,859.2 | 2,037.3 | 4,269.0 | 6,733.4 | 6,355.0 | 5,997.8 | 5,660.8 | 5,342.6 |
| EBIT, % | 13.51 | 17.5 | 12.97 | 3.28 | 6.42 | 10.74 | 10.74 | 10.74 | 10.74 | 10.74 |
| Total Cash | 14,127.1 | 6,854.1 | 9,856.2 | 11,433.4 | 9,626.0 | 9,578.6 | 9,040.3 | 8,532.2 | 8,052.7 | 7,600.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 13,321.8 | 8,692.5 | 9,914.4 | 10,508.0 | 10,134.0 | 9,774.0 | 9,224.7 | 8,706.3 | 8,217.0 | 7,755.2 |
| Account Receivables, % | 14.84 | 14.58 | 16.36 | 16.9 | 15.25 | 15.59 | 15.59 | 15.59 | 15.59 | 15.59 |
| Inventories | 18,453.8 | 11,293.8 | 12,548.7 | 13,805.3 | 13,038.0 | 12,796.6 | 12,077.5 | 11,398.7 | 10,758.1 | 10,153.6 |
| Inventories, % | 20.56 | 18.94 | 20.71 | 22.2 | 19.62 | 20.4 | 20.4 | 20.4 | 20.4 | 20.4 |
| Accounts Payable | 10,902.7 | 5,204.8 | 5,677.4 | 8,213.0 | 8,563.0 | 7,066.0 | 6,668.9 | 6,294.1 | 5,940.4 | 5,606.6 |
| Accounts Payable, % | 12.15 | 8.73 | 9.37 | 13.21 | 12.89 | 11.27 | 11.27 | 11.27 | 11.27 | 11.27 |
| Capital Expenditure | -5,741.5 | -5,274.9 | -5,999.9 | -8,144.5 | -8,977.0 | -6,490.7 | -6,125.9 | -5,781.7 | -5,456.7 | -5,150.1 |
| Capital Expenditure, % | -6.4 | -8.84 | -9.9 | -13.1 | -13.51 | -10.35 | -10.35 | -10.35 | -10.35 | -10.35 |
| Tax Rate, % | 54.78 | 54.78 | 54.78 | 54.78 | 54.78 | 54.78 | 54.78 | 54.78 | 54.78 | 54.78 |
| EBITAT | 8,997.7 | 10,017.3 | 5,160.1 | -4,472.0 | 1,930.4 | 3,784.7 | 3,572.0 | 3,371.2 | 3,181.8 | 3,003.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -14,218.3 | 14,323.2 | 973.0 | -6,390.8 | -1,736.3 | 235.5 | 1,938.8 | 1,829.9 | 1,727.0 | 1,630.0 |
| WACC, % | 10.75 | 11.06 | 10.63 | 9.71 | 10.34 | 10.5 | 10.5 | 10.5 | 10.5 | 10.5 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 5,305.3 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 1,695 | |||||||||
| Terminal Value | 26,087 | |||||||||
| Present Terminal Value | 15,836 | |||||||||
| Enterprise Value | 21,142 | |||||||||
| Net Debt | 27,101 | |||||||||
| Equity Value | -5,959 | |||||||||
| Diluted Shares Outstanding, MM | 159 | |||||||||
| Equity Value Per Share | -37.51 |
What You Will Receive
- Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financial data for Jubilant Pharmova Limited (JUBLPHARMANS).
- Comprehensive Data: Access to historical performance metrics and future projections (highlighted in the yellow cells).
- Assumption Adjustment: Easily modify forecast parameters such as revenue growth, EBITDA %, and WACC.
- Real-Time Calculations: Immediately observe how your inputs affect the valuation of Jubilant Pharmova Limited (JUBLPHARMANS).
- Professional Solution: Designed specifically for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for ease of understanding and usability, complete with step-by-step guidance.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Jubilant Pharmova Limited (JUBLPHARMANS).
- WACC Calculator: A pre-built Weighted Average Cost of Capital sheet with easily customizable inputs.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Jubilant Pharmova Limited (JUBLPHARMANS).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Jubilant Pharmova Limited's (JUBLPHARMANS) pre-filled financial data and forecasts.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Opt for This Calculator?
- Reliable Data: Authentic Jubilant Pharmova financials provide trustworthy valuation insights.
- Flexible Customization: Modify essential inputs such as growth projections, WACC, and tax rates to fit your analysis.
- Efficiency Boost: Pre-configured calculations save you time and effort by eliminating the need to start anew.
- Professional-Quality Tool: Crafted for investors, analysts, and consulting professionals.
- User-Centric Design: Streamlined interface and clear instructions ensure ease of use for everyone.
Who Should Use This Product?
- Individual Investors: Make informed decisions regarding the buying or selling of Jubilant Pharmova Limited (JUBLPHARMANS) stock.
- Financial Analysts: Enhance valuation processes with ready-to-implement financial models tailored for Jubilant Pharmova Limited (JUBLPHARMANS).
- Consultants: Provide precise valuation insights to clients efficiently and effectively, focusing on Jubilant Pharmova Limited (JUBLPHARMANS).
- Business Owners: Gain insights into how large entities like Jubilant Pharmova Limited (JUBLPHARMANS) are valued to refine your own business strategies.
- Finance Students: Develop valuation skills using real-life data and scenarios related to Jubilant Pharmova Limited (JUBLPHARMANS).
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Jubilant Pharmova Limited (JUBLPHARMANS), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for calculating the Weighted Average Cost of Capital (WACC), featuring key parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that illustrate intrinsic value along with comprehensive calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to aid in thorough analysis.
- Key Ratios: Provides profitability, leverage, and efficiency ratios specific to Jubilant Pharmova Limited (JUBLPHARMANS).
- Dashboard and Charts: A visual overview of valuation outcomes and assumptions, facilitating easy result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.